Drug Trial Radar · NCT04788615
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
Last checked: Nov 20, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
185
Actual
Start
Jul 23, 2021
Primary completion
Nov 4, 2025
Study completion Nov 4, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS patients
Conditions
- Multiple Sclerosis
Interventions
OfatumumabDrug
20mg Subcutaneous injection
First line DMTDrug
any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with no evidence of disease activity (NEDA-3)Time frame: Baseline to 15 month
Locations
41 sites in 4 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Amiens, France
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Clermont-Ferrand, France
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Gonesse, France
Novartis Investigative Site
Grenoble, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Nîmes, France
Novartis Investigative Site
Poissy, France
Novartis Investigative Site
Rennes, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Bayonne, Bayonne Cedex, France
Novartis Investigative Site
Bayreuth, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bielefeld, Germany
Novartis Investigative Site
Dortmund, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Siegen, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Westerstede, Lower Saxony, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Montichiari, BS, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Orbassano, TO, Italy
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Málaga, Spain
Novartis Investigative Site
Seville, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Novartis Investigative Site
Salt, Girona, Spain
Novartis Investigative Site
El Palmar, Murcia, Spain
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.